CuraGen Company Profile
CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company dedicated to improving the lives of patients by developing novel pharmaceutical products that address unmet medical needs. CuraGen’s deep understanding of the human genome has enabled us to gain greater insight into the molecular basis of disease. The Company's therapeutics are based on novel drug targets that are believed to play a role in proven mechanisms underlying disease. CuraGen has translated this understanding into a pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes. The Company’s strategy remains focused on advancing its pipeline of promising therapeutics through clinical and preclinical development. History CuraGen was founded when the massive undertaking to sequence the human genome was just beginning. The Company's strategy was based on discovering novel ways to combat disease through an understanding of how genes and their resulting proteins function within the human genome. CuraGen developed an integrated genomics, proteomics, and bioinformatics technology platform that was used to analyze the human genome, disease models, and therapeutic candidates. This approach led to the identification of disease-related genes and therapeutic targets with the subsequent development of novel pharmaceutical products. Today, CuraGen remains one of the leading genomics-based pharmaceutical companies in the industry with a pipeline of protein, antibody, and small molecule therapeutics. The Company is headquartered in Branford, CT.
322 East Main Street
United States of America
Phone: (888) 436-6642 or (203) 481-1104
Fax: (203) 483-2552
Canaan Partners promoted Tim Shannon to general partner and Julie Papanek to principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp. through its sale to ...
Drugs and Medications
CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company dedicated to improving the lives of patients by developing novel pharmaceutical products that address unmet medical needs. CuraGen’...
TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing ...
More Information about "CuraGen" on BioPortfolio
We have published hundreds of CuraGen news stories on BioPortfolio along with dozens of CuraGen Clinical Trials and PubMed Articles about CuraGen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CuraGen Companies in our database. You can also find out about relevant CuraGen Drugs and Medications on this site too.